Capricor Therapeutics, Inc.

3.60 USD
-0.09 (-2.44%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Capricor Therapeutics, Inc. stock is up 28.57% since 30 days ago. The next earnings date is Mar 13, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 23.81% of the previous 21 December’s closed higher than November.

About Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. focuses on the development of transformative cell and exosome-based therapeutics. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD) The company also develops CAP-2003 that is in pre-clinical development for the. treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19.